GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the second horse in its expanded trial for West Nile virus encephalitis recovered completely within 72 hours after starting GenoMed's treatment.

On Saturday afternoon this past weekend, a horse owner in Idaho telephoned Dr. Randy Bean to say that his horse could no longer walk straight. The horse had not been vaccinated for West Nile virus, and the diagnosis was presumed West Nile virus encephalitis. The usual treatment for a horse with WNV costs about $700, and includes antiserum and intravenous dexamethasone. The owner didn't want to spend that much money on his horse. Dr. Bean, who had recently treated another horse with GenoMed's approach, encouraged the owner not to just let his horse die, but to try GenoMed's treatment, which costs $10 a day.

Within 72 hours, the horse was fully recovered.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. Dr. Bean feels that GenoMed's treatment made the difference, and is now calling for a wider trial of GenoMed's approach in horses.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "I'm delighted that Dr. Bean has managed to cure a second horse with presumed WNV using our approach. I'm hoping our treatment finally gets a fair trial this year."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

###

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website, genomed, at any time. Horse owners are encouraged to contact Dr. Moskowitz or Dr. Bean directly (see contact information above) to discuss specific medications and dosing.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

For further information please visit:
GenoMed

Tag Cloud